Please login to the form below

Not currently logged in
Email:
Password:

CAR-Ts

This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.

Regeneron's bispecific for lymphoma works in CAR-T failures

Regeneron's bispecific for lymphoma works in CAR-T failures

At the moment, Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) are the CAR-Ts that have been approved to treat DLBCL, with pivotal trials showing that they can ... In this trial, two patients who failed CAR-T

Latest news

  • Encouraging early data for Amgen’s BiTE therapies Encouraging early data for Amgen’s BiTE therapies

    The potential is for the treatments to show superior efficacy to traditional antibodies, while having easier administration and fewer side-effects than CAR-Ts. ... If the BiTE technology is to mount a strong challenge to CAR-Ts, Amgen will want to

  • Bluebird’s myeloma CAR-T safety ‘could support outpatient use’ Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

    prior to the CAR-T and had a minimum of six months’ follow-up after bb2121 dosing. ... Along with CAR-Ts such as Novartis/Poseida’s P-BCMA-01 and Johnson &Johnson’s LCAR-B38M –incudes other therapeutic approaches in development include

  • Gracell Bio developing faster, cheaper CAR-T production Gracell Bio developing faster, cheaper CAR-T production

    Gracell confirmed that the tech is not only compatible with the CAR-Ts that are already marketed, but it improves effectiveness of the CAR-Ts in both ALL and NHL. ... The lab modified Novartis' Kymriah and tested the cell therapy in 25 patients, but

  • Poseida gets Novartis backing for myleoma CAR-T challenger Poseida gets Novartis backing for myleoma CAR-T challenger

    in single-treatment cures for numerous oncologic indications and orphan genetic diseases, with an initial focus on chimeric antigen receptor T cell (CAR-T) therapies.”. ... The next generation of CAR-Ts are likely to be ‘off the shelf’ allogeneic

  • CAR-T player Autolus seeks $100m from follow-on financing CAR-T player Autolus seeks $100m from follow-on financing

    approved CAR-T Kymriah (tisagenlecleucel) – which recently generated results in a phase 1/2 trial conducted at University College London. ... in paediatric ALL and diffuse large B cell lymphoma (DLBCL), as well as to continue development of two other

More from news
Approximately 9 fully matching, plus 28 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics